Background
Distinct monocyte subsets predict cardiovascular risk and contribute to heart failure progression in murine models but have not been examined in clinical acute decompensated heart failure (ADHF).
Methods and Results
Blood samples were obtained from 11 healthy controls (HC) and at admission and discharge in 19 ADHF patients. Serological markers of inflammation were assessed on admission and discharge. Monocyte populations were defined using flow cytometry for cell-surface expression of CD14 and CD16: CD14++CD16− (classical), CD14++CD16+ (intermediate), and CD14+CD16++ (non-classical). In ADHF patients, C-reactive protein (CRP) and IL-6 were higher compared with HC (both p<0.001), and decreased from admission to discharge (CRP: 12.1±10.1 to 8.6±8.4 mg/L, p=0.005; IL-6: 19.8±34.5 to 7.1±4.7 pg/ml, p=0.08). In ADHF patients, the admission proportion of CD14++CD16-monocytes was lower (68% vs. 85%, p< 0.001) and CD14++CD16+ (15% vs. 8%, p=0.002) and CD14+CD16++ (17% vs. 7%, p=0.07) monocytes higher compared with HC. Additionally, the proportion of CD14++CD16− monocytes increased (68% to 79%, p=0.04) and the CD14+CD16++ monocytes decreased (17% to 7%, p=0.049) between admission and discharge.
Conclusions
Following standard treatment of ADHF, the monocyte profile and circulating inflammatory markers shifts to more closely resemble those of HC, suggesting a resolving acute inflammatory state. Functional studies are warranted to understand how specific monocyte subsets and systemic inflammation may contribute to ADHF pathophysiology.